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                        POST STROKE DEPRESSION
          INCIDENCE AND ASSOCIATIONS
     INTRODUCTION:
A Stroke or cerebro vascular accident is defined as abrupt onset of a neurologic deficit that is 
attributable to a focal vascular pathology. Cerebrovascular diseases include
           1.Ischemic stroke
            2.Hemorrhagic stroke
            3.Cerebrovascular  anomalies------intra  cranial  aneurysm  and  arterio  venous 
malformations. They are the major cause of disability. The incidence of stroke increases with 
age and the number of strokes is projected to increase as elderly population grows. The clinical 
manifestation of stroke are highly variable because of the complex anatomy of the brain and its 
vasculature.
                     Cerebral ischemia is caused by a reduction  in blood flow that lasts longer than 
several seconds. Neurologic symptoms are manifest within seconds because neurons lack 
glycogen ,so energy failure is rapid. When blood flow is quickly restored ,brain tissue can 
recover  fully  and  the  patients  symptom  are  only  transient  called  transient  ischemic 
attacks(TIA).Typically TIA signs and symptoms lasts for 5 to 15 minutes but by definition 
must lasts <24 hours.
                    If the cessation of blood flow lasts for more than a few minutes ,infarction 
results.  Stroke  has  occurred if  the  neurologic  signs  and symptoms lasts  longer  than 24 
hours. Infarction is usually  caused by thrombosis of the cerebral vessels themselves or by 
emboli  from  a  proximal  arterial  source  or  the  heart.  Cerebral  hemorrhage  produces 
neurologic  symptoms  by  producing  a  mass  effect  on  neural  structures  and  vascular 
insufficiency.
                   Rehabilitation after stroke begins as soon as the diagnosis of the stroke is  
established and as soon as any life threatening neurological or medical complications have 
been stabilised. DEPRESSIVE  SYMPTOMS are common after stroke occurring in over 
25%  of  patients.  Stroke  patients  should  be  questioned  and  screened  for  depression. 
Depression  is  common  following  left  hemisphere  stroke  especially  in  the  frontal  lobe, 
possibly caused by disruption of catecholamine pathways.
                 Treatment with antidepressants is often successful in ameliorating symptoms. 
Appropriate diagnosis and treatment of depression may bring substantial benefits to persons 
recovering from stroke by improving their medical status ,enhancing their quality of life and 
reducing their disability.
                                    
    AIM OF THE STUDY
1.  TO FIND OUT THE INCIDENCE OF DEPRESSION IN STROKE 
      PATIENTS.
2.  TO FIND OUT THE HEMISPHERE OF THE BRAIN COMMONLY  
           ASSOCIATED WITH POST STROKE DEPRESSION
3. TO INCREASE THE AWARENESS  AND IMPORTANCE OF      
      ANTIDEPRESSANTS IN STROKE PATIENTS..
                      
 REVIEW OF LITERATURE
 STROKE FACTS:    
          The most common site for a stroke to occur is in the distribution of middle cerebral 
artery which supplies much of the frontal ,temporal,and parietal lobes of the brain as well as 
the subcortical ganglia.
ETIOLOGY:
        It is essential to establish the cause to reduce the risk of recurrence.
85% of CVA are  infarct  and  remaining 15% of cases are hemorrhagic. 
      INFARCT:
        1.Thrombosis:
                Lacunar stroke[small vessel]
      Large vessel thrombosis 
Dehydration
           2.Embolic occlusion:
                 Artery to artery:
                      [a]Carotid bifurcation
                      [b]Aortic arch
                      [c]Arterial dissection
              Cardio embolic:
                                      [a]Atrial fibrillation
                                      [b]Mural thrombus.
                                      [c]Myocardial infarction
                                      [d]Dilated cardiomyopathy.
                                      [e]Valvular lesions:----Mitral stenosis,
                                                                           Mechanical valve,
                                                                           Bacterial endocarditis .
                                      [f]Paradoxical embolus:Atrial septal defect,
                                                                            Patent foramen ovale.
                                          Emboli from the heart most often lodge in the middle cerebral 
artery,the posterior cerebral artery or one of their branches. Infrequently anterior cerebral 
artery territory is involved.The most significant causes of cardioembolic stroke in most of 
the  world  are  non  rheumatic  atrial  fibrillation[Non  valvular],Myocardial  infarction, 
prosthetic  valves,Rheumatic  heart  disease  and  ischemic  cardiomyopathy.Non  rheumatic 
atrial fibrillation is the most common cause of cerebral embolism overall. Patient with atrial 
fibrillation have an annual risk of stroke of 5%.
         Other uncommon causes of stroke are:
         1.HYPERCOAGULABLE DISORDERS:
                                        Protein C deficiency.
                                        Protein S deficiency
                                        Anti thrombin III deficiency.
                                        Anti phospholipid syndrome
                                        Factor V Leiden mutation
                                        Prothrombin G 20210 mutation.
                                        Systemic malignancy.
                                        Sickle cell anaemia.
                                        Polycythemia vera.
                                         Systemic lupus erythematosus.
                                         Homocysteinemia.
                                         Disseminated intra vascular coagulation.
                                         Thrombotic thrombocytopenic purpura.
                                         Nephrotic syndrome.
2.VENOUS SINOUS THROMBOSIS
3.FIBRO MUSCULAR DYSPLASIA:
4.VASCULITIS:
       [a]Systemic vasculitis:
                            Polyarteritis Nodosa
                           Wegners Granulomatosis
                            Takayasu arteritis
                            Giant cell arteritis
       [b]Primary CNS vasculitis.
       [c]Meningitis[Syphilis, tuberculosis,fungal,bacterial,Zoster]
       [d]Cardiogenic:
                        Mitral valve calcification.
                        Atrial Myxoma
                        Marantic Endocarditis.
5.DRUGS
               Cocaine, amphetamine
6.ECLAMPSIA  
                       
          HEMORRHAGIC STROKE:
                 Aneurysmal subarachnoid hemorrhage is the most important treatable condition 
followed by hypertensive intracranial hemorrhage.
CAUSES OF INTRA CRANIAL HEMORRHAGE:
                     Head trauma
                     Hypertensive Hemorrhage[Putamen,Globus pallidus,Thalamus] 
                     Transformation of prior infarction. 
                     Metastatic brain tumour[lung CA ,melanoma]
                     Coagulopathy
                     Drugs[cocaine, amphetamine]
                     Arterio venous malformations
                     Aneurysm,
                           Amyloid angiopathy.
                           Cavernous angioma.
                           Dural arterio venous fistula
                           Capillary Telangiectasias.
    RISK FACTORS FOR STROKE:
                 Identification and control of modifiable risk factors is the best strategy to reduce 
the burden of the stroke as the total number of  strokes could be reduced substantially by 
these means
              ATHEROSCLEROSIS RISK FACTORS:
                                 Older age,Family history of thrombotic stroke,Diabetes 
mellitus,Hypertension,Tobacco smoking,abnormal blood cholesterol particularly low HDL 
and high LDL[37,43].
              HYPERTENSION is the most significant of risk factors.
STROKE:   RISK FACTORS
RISK FACTOR RELATIVE RISK RELATIVE RISK 
REDUCTION WITH 
TREATMENT.
1.Hypertension 2-5 38%
2.Atrial fibrillation 1.8-2.9 68% warfarin
21%Aspirin
3.Diabetes 1.8-6 No proven effect
4.Smoking 1.8 50% at 1 year
Baseline risk at 5 years 
post cessation
5.Hyperlipidemia 1.8-2.6 10-29%
6.Asymptomatic carotid 
stenosis
2 53%
7.Symptomatic carotid 
stenosis[70-99%]
65% at 2 years
8.Symptomatic carotid 
stenosis[50-69%]
29% at 5 years
PATHOPHYSIOLOGY OF ISCHEMIC STROKE:
     Acute occlusion  of an intra cranial vessel causes reduction in blood flow to the brain 
region it supplies.The magnitude of flow reduction is a function of collateral blood flow and 
this depends on individual vascular anatomy and the site of occlusion.
     A fall in cerebral blood flow to
               Zero-----Death of brain tissue within 4-10 minutes.
               Less than 16-18 ml/100g tissue/minute-----Infarction within an hour
           If blood flow is returned  prior to a significant amount of cell death,the patient may 
experience only transient symptoms, called transient ischemic attack.Tissue surrounding the 
core region of infarction is ischemic but reversibly dysfunctional and it is referred to as the 
ischemic penumbra. The penumbra may be imaged by using perfusion  diffusion imaging 
with MRI. The ischemic penumbra will eventually infarct if no change in flow occurs and 
hence saving the ischemic penumbra is the goal of thrombolytic therapy.
                                                                         
CLINICAL FEATURES:
                Symptoms of stroke appear suddenly and often there is more than one symptom at 
the same time.
        1.Sudden numbness or weakness of the face ,arm or leg especially on one side of the 
body.
         2.sudden confusion ,difficulty in talking or understanding speech 
        3.Sudden difficulty in seeing in one or both eyes.
        4.Sudden difficulty in walking ,dizziness or loss of balance or coordination.
        5.Sudden severe headache with no known cause.
     
          Clinical examination should be focused on the peripheral and cervical vascular 
system[carotid  auscultation  for  bruits,  blood  pressure],the 
heart[dysrhythmia,murmurs],extremities  [peripheral  emboli]  and  retina[effects  of 
hypertension and cholesterol emboli] 
   
         Disabilities that can result from a stroke include paralysis,cognitive deficits,speech 
problems,emotional  difficulties,fatigue  and  daily  living  problems.  Many  stroke  patients 
requires psychiatric help for post stroke disabilities like depression,anxiety,frustration and 
anger.Because  stroke  survivors  often  have  complex  rehabilitation  needs,  progress  and 
recovery are unique for each person.
DIFFERENTIAL DIAGNOSIS:
          1.Post ictal Todd’s  paresis following seizures.
          2.Brain tumours may present with acute neurologic symptoms due to 
              hemorrhage,seizures,or hydrocephalous
         3.Migraine  can mimic cerebral  ischemia,even in  patients  without  a  significant 
migraine history. When it develops without head pain [acephalgic migraine],the diagnosis 
may  remain  elusive.The  diagnosis  of  migraine  becomes  more  secure  as  the  cortical 
disturbance  begins  to  cross  vascular  boundaries  or  if  typical  visual  symptoms  are 
present,such as scintillating scotomata.
        4.Metabolic  encephalopathies  produce  fluctuating  mental  status  without  focal 
neurologic findings.
INVESTIGATIONS:
     Once the diagnosis of stroke is made,a brain imaging study is necessary to determine if 
the cause of stroke is ischemic or hemorrhagic. Computed tomography[CT] imaging of the 
brain is the standard imaging modality to detect the presence or absence of  intracranial 
hemorrhage. Early CT scaning of brain will not pick up the infarct  but helps to exclude 
hemorrhage.Infarct  may not be seen reliably for 24-48 hours in CT brain.
                  MRI reliably documents the extent and location of infarction in all areas of brain 
,including  the  posterior  fossa  and  cortical  surface.  MRI  is  less  sensitive  than  CT  for 
detecting acute blood.
Other baseline investigations to be done are
          Chest X ray
           ECG,
           Urine analysis,
           Complete blood count,
           Serum electrolytes ,
           Blood urea nitrogen, 
           Creatinine,
           Blood sugar,
           Serologic tests for syphilis,
        Serum lipid profile
  
                       Diffusion weighted imaging is more sensitive for early brain infarction than 
standard MR sequences ,as is FLAIR[Fluid Attenuated Inversion Recovery] imaging.
      
                           Conventional X ray cerebral angiography is the “gold standard” for 
identifying and quantifying atherosclerotic stenosis of the cerebral arteries
                Paradoxical embolization  is identified using bubble contrast echocardiography.It 
is done by intravenous injection of agitated saline coupled with either transthoracic or trans 
esophageal echocardiography.It can reveal a cardiac right to left shunt via a patent foramen 
ovale or atrial septal defect.
          
 
TREATMENT:
                        After the clinical diagnosis of stroke is made, an orderly process of  
evaluation and treatment should follow.The first goal is to prevent or reverse brain injury . 
After initial stabilization, an emergency noncontrast CT scan brain should be performed to 
differentiate ischemic from hemorrhagic stroke.There are no reliable clinical findings that 
conclusively  separate  ischemia  from  hemorrhage,  although  a  more  depressed  level  of 
conciousness and higher initial blood pressure favour hemorrhage,and a deficit that remits 
suggests ischemia.
                   
             Treatment designed to reverse or lessen the amount of tissue infarction fall within 
five categories:[36]
             1.Medical support.
             2.Thrombolysis
             3.Anticoagulation
             4.Antiplatelet agents
             5.Neuroprotection.
          1.Medical support:
             When cerebral infarction occurs, the immediate goal is to optimize cerebral 
perfusion in the surrounding ischemic penumbra.Prevent the common complications of bed 
ridden  patients  like  infections[pneumonia,  UTI   and  skin  infections]  and  deep  vein 
thrombosis with pulmonary  embolism.Pneumatic compression stockings prevent deep vein 
thrombosis. Subcutaneous heparin appears to be safe as well.
             Blood pressure  should  be  lowered  if  there  is  malignant  hypertension,  or 
concomitant myocardial ischemia or if blood pressure is more than 185/110 mmHg and 
thrombolytic therapy is anticipated.Fever and hyperthermia are detrimental and should be 
kept under control.
              Cerebral edema peaks on the second or third day to cause obtundation or brain 
herniation. The larger the infarct,the greater the likelihood that clinically significant  edema 
will  develop.Even  small  amount  of  cerebellar  infarction  with  edema  acutely  increases 
intracranial pressure.Treat with water restriction and IV mannitol.
2.Thrombolysis:
           If the stroke is ischemic, administration of tissue plasminogen activator may be 
beneficial in restoring cerebral perfusion. IV r tpa 0.9 mg/kg  10% as bolus, remainder over 
60 minutes is given for stroke patients within 3 hours of onset  [31]
3.Anti platelet agents:
            Aspirin when used within 48 hours of stroke onset reduced both stroke recurrence 
risk and mortality. [35,42]
4.Anti coagulation:
            Heparin given subcutaneously afforded no additional benefits over aspirin and 
increases bleeding rate in ischemic stroke.[32]
            Anti thrombotic prophylaxis in atrial fibrillation:
AGE RISK FACTORS RECOMMENDATION
<65 years 1 or more risk factors
0
Warfarin INR 2-3
Aspirin or no treatment
65-75 years 1 or more risk factors
0
Warfarin INR 2-3
Warfarin INR 2-3 or 
aspirin
>75 years Warfarin INR 2-3
Risk factors include previous transient ischemic attack or stroke,hypertension,heart 
failure,diabetes,clinical coronary artery disease,mitral stenosis,prosthetic heart valves or 
thyrotoxicosis[34,38,39,41]
 5.Neuroprotection:
               Neuroprotection  is the concept of providing a treatment that prolongs the brain’s 
tolerance to ischemia. Hypothermia may be useful.[40]
CAROTID BIFURCATION ATHEROSCLEROSIS:
                                                    It is the most common source of artey to artery embolus  
and  specific  treatments  have  proven  efficacy  in  reducing  risk.Carotid  atherosclerosis 
produces an estimated 5% of ischemic stroke and the risk of stroke rises, the higher the 
degree  of  carotid  narrowing.Carotid  disease  can  be  classified  by  whether  the  stenosis 
symptomatic or asymptomatic and by the degree of stenosis[33].
          Treatment:
                          Carotid endarterectomy
                           Balloon angioplasty coupled with stenting.
TREATMENT OF INTRA CRANIAL HEMORRHAGE:
                                      In patients with acute sub arachnoid hemorrhage, blood pressure 
should  be   lowered  to  a  normal  range  with  nonvasodilating  agents  such  as 
Nicardipine,labetolol  or  esmolol .Patients  with cerebellar  hemorrhage or  with depressed 
mental  status  and  radiographic  evidence  of  hydrocephalous  should  undergo  urgent 
neurosurgical evaluation.
                  Stuporous or comatose patients generally are treated presumptively for elevated 
intracranial pressure,with tracheal intubation and hyperventilation,mannitol administration 
and elevation of the head end of the bed while surgical consultation is obtained. 
REHABILITATION:
              It improves neurologic outcomes and reduces mortality .Proper rehabilitation of the stroke 
patient includes early physical,occupational and speech therapy.The goal of rehabilitation is to 
return the patient to home and to maximize recovery by providing a safe,progressive regimen suited 
to the individual patient.
DEPRESSION FACTS:
     Mood disorders are characterized by a disturbance in the regulation of mood, behaviour 
and affect.Mood disorders are subdivided into
            1.Depressive disorders
             2.Bipolar disorders
            3.Depression in association with medical illness or substance abuse.
INTRODUCTION:
        Depression is a serious medical condition that affects thought, feelings and the ability 
to function in everyday life. It can occur at any age. NIMH [National Institute of Mental 
Health] sponsored studies  showed 10% of American adults have experience some form of 
depression every year.An interaction between genetic predisposition and life style  appears 
to determine a persons level of risk  for depression. Episodes of depression may then be 
triggered by stress, difficult life events, side effects of medications or other environmental 
factors.
        In the global burden of disease study conducted by WHO , unipolar major depression 
ranked fourth among all diseases in terms of DALY(Disability Adjusted Life Years)and 
was projected to rank second by year 2020.
     DEPRESSION IN ASSOCIATION WITH MEDICAL ILLNESS:
            1.CARDIOVASCULAR SYSTEM:
                                  20 to 30% of cardiac patients(Unstable angina, Myocardial infarction, 
Cardiac transplant) 
            2.MALIGNANCY:
                            The prevalence of depression is  25% in cancer patients commonly with  
pancreas and oropharaynx cancer.
           3.CENTRAL NERVOUS SYSTEM:
                                  Neurological disorders like cerebro vascular disease, Parkinson’s 
disease,  Dementia,  Multiple  sclerosis  and  traumatic  brain  injury  are  associated  with 
depression. 
            4.DIABETES MELLITUS:
                                   Depression is seen in 8 to 27% of diabetic patients with severity of 
mood  state  correlating  with  the  level  of  hyperglycemia  and  the  presence  of  diabetic 
complications.
            5.ENDOCRINE:
                                 Hypothyroidism is commonly associated with  depression.  
            6. INFECTIONS:
                                   Life time prevalence of depression in HIV positive individuals is 22  
to 45%.Chronic Hepatitis C infection is also associated with depression which may worsen 
with Interferon alpha treatment.
                Depressed patients often show decreased variability in heart rate[ an index of 
reduced  parasympathetic  nervous  system  activity]  and  may  predispose  individuals  to 
ventricular  arrhythmia  and  increased  morbidity  .Depression  also  increases  the  risk  of 
coronary artery disease due to increased serotonin induced platelet aggregation.
CLINICAL MANIFESTATIONS:
                                MAJOR DEPRESSION is defined as depressed mood on a daily basis 
for  a  minimum duration  of  2  weeks.  Patient  with  depression  have  a  profound  loss  of 
pleasure in all  enjoyable activities,  exhibit  early  morning awakening and often notice a 
diurnal  variation  in  mood(worse  in  morning  hours).Approximately  15%  of  population 
experiences  a  major  depressive  episode  at  some  point  in  life.Depression  is  often 
undiagnosed and even more frequently   it  is  treated inadequately.4 to 5% of depressed 
patients commits suicide. 
                  The term MINOR DEPRESSION is used  for individuals who experience atleast 
2 depressive symptoms for 2 weeks.
                      Depression is common in women and increases with age in both sexes
                     Physicians should also asses the risk of suicide by direct questioning,as  
patients are often reluctant to verbalize such thoughts without prompting. If significant risk 
factors  exists, the patient must be referred to a mental health specialist for immediate care.
                Dysthymic disorder consists of a pattern of chronic [at least 2 years] ongoing,mild 
depressive symptoms  that are less severe  and less disabling than those found in major 
depression.These two conditions can occur together called ‘Double depression”.
             Negative life events can precipitate and contribute to depression, but genetic factors 
influence the sensitivity of individuals to these stressful events.In most cases ,both biologic 
and  psychosocial  factors  are  involved  in  the  precipitation  and  unfolding  of  depressive 
episodes.The  most  important  stressors  appear  to  involve death  of  a  relative,  assault,  or 
severe marital or relationship problems.
            Unipolar   depressive  disorders  usually  begin  in  early  adulthood and recur 
episodically over the course of a life time.The best predictor of future risk is the number of 
past  episodes.The  duration  of  an  untreated  episode  varies  greatly,ranging  from  a  few 
months to more than a year.The pattern of recurrence and clinical progression  is variable.In 
a minority of patients, a severe depressive episode may progress to a psychotic state .In 
elderly patients, depressive symptoms may be associated with cognitive deficits  mimicking 
dementia[pseudo dementia] .A seasonable pattern of depression ,called seasonal affective 
disorder, may manifest with onset and remission of episodes at predictable times of the 
year.
                   
      SYMPTOMS OF DEPRESSION:
    1.Persistent sad, anxious or empty mood.
     2.Thoughts of death or suicide or suicide attempts.
    3.Feeling of hopelessness, pessimism
    4.Feeling of guilt, worthlessness, hopelessness.
    5.Loss of interest or pleasure in hobbies and activities that were once enjoyed, including 
sex,.
     6.Decreased energy, fatigue, being slowed down.
     7.Difficulty in concentrating, remembering, and making decisions.
     8.Restlessness, irritability
     9.Insomnia, early morning awakening, or oversleeping.
   10.Appetite or weight changes.
  If 5 or more symptoms are present everyday for atleast  2 weeks and interfere with daily 
routine activities, seek an evaluation for depression.
ETIOLOGY:
         Although evidence for genetic transmission of unipolar depression is not as strong as 
in bipolar disorder,monozygotic twins have a higher concordance rate [46%] than dizygotic 
siblings[20%].A functional polymorphism in the serotonin transporter[5-HTT] gene may 
interact with stressful life events to markedly increase the risk of depression and suicide. 
PET studies show  decreased metabolic activity in the caudate nuclei and frontal lobes in 
depressed patients that returns to normal with recovery.
             Altered noradrenergic activity , including  increased binding to alpha1,2 and beta 
adrenergic receptors in the cerebral cortex and decreased numbers of noradrenergic neurons 
in  the  locus  ceruleus  is  noticed in  brains  of  depressed patients.Involvment  of  serotonin 
system is suggested by findings of reduced plasma tryptophan levels, and decreased CSF 
levels of 5 hydroxy indole acetic acid.
TREATMENT:
            Treatment planning requires coordination of short term symptom remission with 
long  term  maintenance  strategies  designed  to  prevent  recurrence.The  most  effective 
intervention for achieving remission and preventing relapse is medication, but combined 
treatment,incorporating psychotherapy to help the patient cope with decreased self esteem 
and demoralization ,improves outcome.
        
              Compliance of treatment and outcome improves with  
          1.Increased intensity and frequency of visits during the first 4-6 weeks of treatment
          2.Supplemental educational material
         3.Psychiatric consultation as needed.
              
           Between 60-70% of all depressed patients respond to any drug chosen,if it is given in 
a sufficient dose for 6-8 weeks.A rational approach to selecting which antidepressants to 
use involves matching the patients preference and medical history with the metabolic and 
side effect profile of the drug.A previous response or a family history of a positive response 
to a specific antidepressant would suggest that, that drug be tried first.
CLASSIFICATION:
   Anti depressants are of two types: 
                         [a]MAO INHIBITORS
                         [b]TRICYCLIC AND RELATED ANTIDEPRESSANTS
[a]    MAO INHIBITORS:
             Non selective:
                          [1]Hydrazines: Phenelzine
                                                 :Isocarboxazid
                          [2]Non-Hydrazine:Tranylcypromine
                Selective:
                          MAO-A:     Clorgiline
                                              Moclobemide
                          MAO-B:      Selegiline[Deprenyl]
[b]  TRICYCLIC AND RELATED ANTIDEPRESSANTS:
                1.Noradrenaline and serotonin reuptake inhibitors:
                                             Imipramine
                                             Amitryptline
                                             Trimipramine
                                             Doxepine
                                             Clomipramine
                                             Dothiepin
                 2.Noradrenaline reuptake inhibitors: 
                                              Nortriptyline
                                             Desipramine
                                             Protriptyline
                                             Amoxapine.
                  3.Selective serotonin reuptake inhibitors:
                                            Fluoxetine
                                            Fluvoxamine
                                            Paroxetine
                   4.Atypical antidepressants:
                                           Trazodone
                                           Bupropion
                                           Mianserin
                                           Tianeptine.
Newer compounds with atypical properties:
                                          Venlafaxine
                                          Mirtazapine
                                          Nefazodone
                                         Citalopram
                                          Sertraline
           Tricyclic antidepressants are not euphoriants but only antidepressants. Sedative 
property varies among different compounds.The more sedative ones are suitable for 
depressed patients showing anxiety and agitation. The less sedative or stimulant ones are 
better for withdrawn and retarded patients.
            Inhibition of Nor adrenaline and serotonin uptake is associated with antidepressant 
action.Inhibition of serotonin uptake may be responsible for sedation. 
                        In individuals with suicidal ideation,  particular attention should be paid to 
choosing a drug with low toxicity if taken in overdose. The SSRI’s and other 
antidepressants are distinctly safe in this regard.
                 Tricyclic antidepressants are contraindicated  in patients with Bundle branch 
blocks and TCA induced tachycardia is an additional concern in patients with CCF.
                       Selective serotonin receptor uptake inhibitor[SSRI]  appear not to induce 
ECG changes or adverse cardiac events and thus are reasonable first line drugs for patients 
at risk for TCA related complications. SSRI’s may interfere with  hepatic metabolism of 
anticoagulants however,causing increased anticoagulation.
                      The principal disadvantages of TCAs are antihistamine side effects (sedation) 
and anticholinergic side effects (constipation, dry mouth, urinary hesitancy, and blurred 
vision). Severe cardiac toxicity due to conduction block or arrhythmias can also occur but is 
uncommon at therapeutic levels. TCAs are probably contraindicated in patients with 
cardiovascular risk factors. Tricyclic agents are lethal in overdose, with desipramine carrying 
the greatest risk. Prescribing only a 10-day supply may be judicious. Most patients require a 
daily dose of 150 to 200 mg of imipramine or amitriptyline or its equivalent to achieve a 
therapeutic blood level of 150 to 300 ng/mL and a satisfactory remission; some patients show a 
partial effect at lower doses. Geriatric patients in particular may require a low starting dose and 
slow escalation.
                                   Second-generation antidepressants include amoxapine, maprotiline, 
trazodone, and bupropion. Amoxapine is a dibenzoxazepine derivative that blocks 
norepinephrine and serotonin reuptake and has a metabolite that shows a degree of dopamine 
blockade. Long-term use of this drug carries a risk of tardive dyskinesia. Maprotiline is a 
potent noradrenergic reuptake blocker that has little anticholinergic effect but may produce 
seizures.
                                       Bupropion is a novel antidepressant whose mechanism of action is 
thought to involve enhancement of noradrenergic function. It has no anticholinergic, sedating, 
or orthostatic side effects and has a low incidence of sexual side effects. It may, however, be 
associated with aversive stimulant-like side effects, may lower seizure threshold, and has an 
exceptionally short half-life, requiring multiple dosing. An extended-release preparation is 
available.
     
                          SSRIs such as fluoxetine, sertraline, paroxetine, and citalopram cause a lower 
frequency of anticholinergic, sedating, and cardiovascular side effects but a possibly greater 
incidence of gastrointestinal complaints, sleep impairment, and sexual dysfunction than do 
TCAs.
                    Akathisia, involving an inner sense of restlessness and anxiety, may also be more 
common, particularly during the first week of treatment. A serious concern, aside from drug 
interaction, is the risk of "serotonin syndrome," thought to result from hyperstimulation of 
brainstem 5HT1A receptors and characterized by myoclonus, agitation, abdominal cramping, 
hyperpyrexia, hypertension, and potentially death. Combinations of serotonergic agonists 
should be monitored closely for this reason. Considerations such as half-life, compliance, 
toxicity, and drug-drug interactions may guide the choice of a particular SSRI.
                                    Fluoxetine and its principal active metabolite, norfluoxetine, for  
example, have a combined half-life of almost 7 days, resulting in a delay of 5 weeks before 
steady-state levels are achieved and a similar delay for complete drug excretion once its use is 
discontinued.  All  the  SSRIs  may  impair  sexual  function,  resulting  in  diminished  libido, 
impotence,  or  difficulty  in  achieving  orgasm.  Sexual  dysfunction  frequently  results  in 
noncompliance  and  should  be  asked  about  specifically  in  patients  using  SSRIs.  Sexual 
dysfunction can sometimes be ameliorated by lowering the dose, by instituting drug holidays 
over the weekend (two or three times a month), or by treatment with amantadine (100 mg tid), 
bethanechol (25 mg tid), or buspirone (10 mg tid).
                             Paroxetine appears to be more anticholinergic than either fluoxetine or  
sertraline, and sertraline carries a lower risk of producing an adverse drug interaction than the 
other two. Rare side effects of SSRIs include vasospastic angina and alterations of prothrombin 
time. Citalopram is  the most specific of currently  available SSRIs and appears to have no 
specific inhibitory effects on the P450 system. Escitalopram is the most specific of currently 
available SSRI’s and appear to have no specific inhibitory effects on the p450 system.
                                         Venlafaxine, like imipramine, blocks the reuptake of both 
norepinephrine and serotonin, but it produces relatively little in the way of traditional tricyclic 
side effects. Unlike the SSRIs, it has a relatively linear dose-response curve. Patients should be 
monitored for  a  possible increase in diastolic  blood pressure,  and multiple  daily  dosing is 
required because of the drug's short half-life. An extended-release form is available and has a 
somewhat lower incidence of gastrointestinal side effects. 
                                           Nefazadone is a selective 5HT2 receptor antagonist that also inhibits 
the presynaptic reuptake of serotonin and norepinephrine. Its side effects are similar to those of 
the SSRIs, and twice-daily dosing produces a steady state within 4 to 5 days. The drug is 
related  structurally  to  trazodone,  which  is  currently  used  more  for  its  sedative  than  its 
antidepressant properties.  Nefazadone appears  to  produce a lower incidence of  sexual  side 
effects than do the SSRIs.                                      
                Mirtazapine is a tetracyclic antidepressant that has a comparatively unique spectrum 
of activity. It increases noradrenergic and serotonergic neurotransmission through a blockade 
of central a2-adrenergic auto- and heteroreceptors and postsynaptic 5HT2 and 5HT3 receptors. 
It is also strongly antihistaminic and, as such, may produce sedation at lower doses.
                         With the exception of citalopram, each of the SSRIs, as well as nefazadone, 
may inhibit  one or more cytochrome P450 enzymes. Depending on the specific isoenzyme 
involved,  the  metabolism of  a  number  of  concomitantly  administered  medications  can  be 
dramatically affected. Fluoxetine and paroxetine, for example, by inhibiting 2D6, can cause 
dramatic  increases  in  the  blood  level  of  type  1C  antiarrhythmics,  while  sertraline  and 
nefazadone,  by  acting  on  3A4,  may alter  blood levels  of  terfenadine,  carbamazepine,  and 
astemizole.  Because many of these compounds have a narrow therapeutic window and can 
cause  iatrogenic  ventricular  arrhythmias  at  toxic  levels,  the  possibility  of  an adverse  drug 
interaction should be considered.
                     Other treatment options include the MAOIs and electroconvulsive therapy. The 
MAOIs are highly effective, particularly in atypical depression, but the risk of hypertensive 
crisis following intake of tyramine-containing food or sympathomimetic drugs makes them 
inappropriate as first-line agents. Common side effects include orthostatic hypotension, weight 
gain, insomnia, and sexual dysfunction. MAOIs should not be used concomitantly with SSRIs, 
because of the risk of serotonin syndrome, or with TCAs, because of possible hyperadrenergic 
effects.  
                          Electroconvulsive therapy is at least as effective as medication, but its use is 
reserved  for  treatment-resistant  cases  and  delusional  depressions.Transcranial  magnetic 
stimulation[TMS] is an investigational treatment of depression that has been shown to have 
efficacy in several controlled trials.
                      Regardless of the medication chosen, the treatment response should be evaluated 
after approximately 2 months of therapy. Three-quarters of patients show an adequate response 
by this time, but if remission is inadequate, the patient should be questioned about medication 
compliance, and an increase in dose should be considered if side effects are not troublesome. If 
there is no improvement, consultation with or referral to a mental health specialist is advised. 
Strategies  for  treatment  then  include  selection  of  an  alternative  drug,  combinations  of 
antidepressants,  and/or  adjunctive  treatment  with other  classes  of  drugs,  including lithium, 
thyroid hormone, and dopamine agonists. Patients whose response to an SSRI disappears over 
time may benefit from the addition of buspirone (10 mg tid) or pindolol (2.5 mg tid) or small 
amounts of a tricyclic antidepressant such as desipramine (25 mg bid or tid). Once significant 
remission is achieved, drug treatment should be continued for at least 6 to 9 months to prevent 
relapse. In patients who have had two or more episodes of depression, indefinite maintenance 
treatment should be considered.
                 It is essential to counsel patients about depression and the medications they are 
receiving. An educational approach is best,  describing what is known about the depressive 
syndrome and how the medications may help. Advice about stress reduction, side effects, and 
expected length of treatment and cautions that alcohol may exacerbate depressive symptoms 
and  impede  drug  response  are  helpful.  Patients  should  be  given  time  to  describe  their 
experience and the impact it has had on them, their family, and their outlook.
 
DEPRESSION AND STROKE:
     
           The common behavioural and cognitive sequelae of stroke include depression, 
psychosis,  anxiety,  personality  change,  aphasia  and  dysprosody  among  others[23]. 
Depression following stroke is one of the most under recognized complication  of a stroke. 
Appropriate  diagnosis  and  treatment  of  depression  improves  the  medical  status,enhance 
their quality of life and reduce their pain and disability .The development of depression 
after a stroke is a serious condition that can have negative  effects on thought, emotions and 
overall  daily  functioning,  particularly  in  the  first  year  following  stroke.  Post  stroke 
depression   is  independent  of  functional  disability,   and  cerebrovascular  risk 
factors(21).Slowness  and  psychomotor  retardation  is  common  in  post  stroke 
depression{18,24}.The Diagnostic and statistical manual-4   distinguishes major depressive 
disorder[idiopathic depression] and mood disorder due  to general medical conditions.
 
 Mimickers:
           Post stroke emotionalism[12], reported in about 10%of stroke patients[House et al 
1989]is an abnormal lability of mood during which the patient laughs or cries for no easily 
discernible reactions. Typically the patient does not feel the expected emotions associated 
with this outward reactions.
                               Apathetic symptoms may be difficult to distinguish from depression. 
Depression  is  characterized  by  a  primary  disorder  of  mood while  apathy  is   largely  a 
disorder  of motivation. Most depressed patients report a subjective sense of unpleasant, 
dysphoric  mood  but  the  apathetic  patient  often  appears  flat,  shallow  and  emotionally 
unconcerned.[27]
INCIDENCE AND DURATION:
                The prevalence rates for  post stroke depression varies enormously [from 5% to 
50%] depending on several factors, including  the criteria used to diagnose depression, area 
of involvement , and how long after the stroke the assessment is made[7,26].
         Around 70 to 80% of  patients with stroke survives. Of those patients who survive the 
stroke, major depression occurs in about 20% of patients.  Major depression is the most 
severe form of clinical depression that we recognize in neuropsychiatry.  Another,  about 
20% of the patients will develop minor depression. Most depression occur within the acute 
period after the  stroke[1,6,24]
        Of the 600,000 American men and women who experience a first or recurrent stroke 
each year, an estimated 10 to 27% experience major depression[2] . An additional 15 to 
40% experience some symptoms of depression within 2 months following a stroke.[3]
          The community based Framingham study diagnosed depression in 47% of 6 month 
stroke survivors. In a population based cohort of Swedish stroke patients  whose mean age 
was 73years,the prevalence of major depression was 25% at hospital discharge,30%at 3 
months after stroke, 16% at 1 year[19]       
           The average duration of major depression in people who have suffered a stroke is 
just under a year.[18].
    AGE
       Younger stroke victims are more likely to become depressed than older stroke victims.
[6]
    SEX:
      Epidemologic  data from around the world demonstrate that major depression is more 
common  in  women  than  in  men[Weissman  and  olfson  1995].  The  same  relationship 
between depression and female gender is also found in stroke patients.[Anderson et al 1995, 
Herrmann et al 1998,Kotila et al 1998,Paradiso and Robinson 1998]
    HEMISPHERE AND AREA:
          The frontal and left hemisphere stroke are strongly associated with depression[8]. A 
large MRI study  from  Finland has reported a significant increase in depression  following 
left  hemisphere  and  frontal  stroke.[9].MRI  has  greater  accuracy  than  CT  and  frontal 
subcortical   circuits  are  recognized  as  the  neuroanatomical  substrate  of  much  of  the 
depression syndrome[10]
            There is significant inverse correlation between severity of depression and distance 
of the lesion from the frontal pole with left hemisphere stroke.[When compared to  right 
hemisphere  stroke][22].The  frontal  lobe  and subcortical  nuclei  are  richly  innervated  by 
monoaminergic amines   serotonin and norepinephrine.  Noradrenergic  and serotonin cell 
bodies originate in the brain stem and send axonal projection through the median fore brain 
bundle to the frontal lobe.Anterior and subcortical lesions could interrupt these ascending 
fibres to a greater extent than posterior and more distally placed lesions.,  resulting in a 
greater likelihood of Post stroke depression.[24].
               Serotonin binding was  higher in right hemisphere injury than left hemisphere 
injury.This  relative  inability  of  the  left  anterior  hemisphere  to  upregulate   serotonin 
receptors after stroke produces depression.[24]  
      
VASCULAR DEPRESSION:
            Depressive symptoms is not an inevitable reaction to the effects of a stroke. But 
depression is  a  separate illness that  can  and should be treated,  even when a person is 
undergoing  post stroke rehabilitation. Depression is caused by biological factors provoked 
by brain injury.
            At 1997, Alexoplus and Krishnan coined the term “VASCULAR DEPRESSION” to 
describe depression associated with stroke. Vascular depression includes both Post stroke 
depression and MRI detected cerebral infarction in which there are no clinical symptoms 
such as focal neurological deficit. When the infarct obstructs neuronal network related to 
mood, the patient is predisposed to depression. Neurological factors are more prominent 
than genetic factors or psychosocial stress in patients with vascular depression.[20]
          Folstein et al found a significantly increased rate of depression in stroke patients 
compared to orthopedic patients despite similar levels of disability, suggesting that mood 
dysregulation is a more specific complication of stroke rather than a general response to 
disability.[24].
EFFECT OF DEPRESSION: 
         Stroke survivors who are also depressed may be less compliant with rehabilitation, 
more  irritable  and  may  experience  personality  change[3].Patients    with  Post  stroke 
depression  have  lower  functional  status,  increased  cognitive  impairment  and  higher 
mortality rates than stroke patients without depression.[13,24].
                        Parikh et al noted the depressed patients were significantly more impaired in 
physical and language functioning 2 years after stroke[25].Morris et al also found 3 fold 
greater mortality  in  the depressed group independent of age,  sex,  type of  stroke,  lesion 
location and size.[14].
TREATMENT:
      Both nortryptline and citalopram have been demonstrated in controlled studies to be 
effective  in  treating   post  stroke  deoression.  Treating  post  stroke  depression,  not  only 
improve the patients mental state that is their mood but it will also improve their physical 
recovery and their cognitive and intellectual recovery from the stroke[6].Those treated for 
depression for 3 months after stroke had longer survival times[15]
           Tricyclic  antidepressants[TCA]   Nortryptline  produces  greater  reduction  in 
depression  compared  to  Selective  serotonin  receptor  uptake  inhibitor[  SSRI] 
Fluoxetine[16].However TCA have significant negative effects on cardiovascular diseases 
while SSRI  are safe in depression in cardiovascular disease[17].The greater safety of SSRI 
in  cardiovascular  disease  is  probably  because  of  their  inhibitory  effects  on  platelet 
activation.The SSRI are also very likely to be safer in stroke disease than TCA and this 
improved safety profile probably makes them the treatment of choice for most people with 
Post stroke depression.
               MATERIAL AND METHODS
    
   This descriptive study is carried out in Stanley medical college hospital during the period 
of  November  2004  to  October  2005.The  stroke  patients  in  both  gender  was  taken  for 
evaluating the incidence of depression after stroke. The hemisphere of the brain commonly 
associated  with depression is  also noted Totally  60 stroke patients  were  evaluated for 
depression.            
      Inclusion criteria:
                        Stroke within the last 30 days
 
       Exclusion criteria:
                        1.Aphasic patients 
                        2.Unconcious patient.
                        3.Heart,Respiratory,kidney,or liver failure
                        4.Severe disabling musculoskeletal disorder or cancer.
                       5.Diagnosis  of  neuro degenerative disorders  such as Parkinsons 
disease,Alzeimer’s disease,Multiple system atrophy or Huntington’s disease
                      6.Pre-existing dementia
                      7.Recurrent unipolar or Bipolar disorder prior to the stroke.
                     8.Patient  taking  drugs  prone  for  depression  like  beta 
blockers,Glucocorticoids,anti convulsants,anti parkinsonian medications.
              The disability of the stroke is divided  into hemiparesis [more than the power 3] 
and hemiplegia [less than or equal to 3] to evaluate whether the disability is associated with 
depression.
           The quantitative assessment of power can be done by grading the  muscle  power as 
suggested by the medical research council.
           Grade 5-------Normal power
           Grade 4--------Movement against resistance
            Grade 3--------Movement against gravity.
            Grade 2------Gravity eliminated movement.[Lateral movements in bed]
            Grade 1---------There is visible or palpable flicker of contraction but no
                                       resultant movement of joint 
                                       .
CRITERIA USED TO DIAGNOSE DEPRESSION
                                                   
     DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS,  IV 
Edition
   1.Depressed mood most of the day, nearly every day, as indicated by either subjective 
report[eg….feels sad or empty] or observation made by others[eg….appears tearful] 
   2.Reccurrent thoughts of death[not just fear of dying],recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide.
   3.Feelings  of  worthlessness  or  excessive  or  inappropriate  guilt[which  may  be 
delusional]nearly everyday[not  merely self reproach or  guilt about being sick]
    4.Markedly diminished interest or pleasure in all, or almost all , activities most of the 
day, nearly  every day[as indicated by either subjective account or observation made by 
others] .
     5.Fatigue or loss of energy nearly every day.
    6.Diminished ability to think or concentrate or indecisiveness, nearly every day[either by 
subjective account or as observed by others]           
    7.Psychomotor agitation or retardation nearly every day[Observable by others,not merely 
subjective feelings of restlessness or being slowed down]
    8.Insomnia or hypersomnia nearly everyday
    9.Significant weight loss when not dieting or weight gain or decrease or increase in 
appetite nearly everyday.  
   
       Five or more of the above symptoms  have been present during the same 2 week period 
and represent a change from previous functioning is needed to diagnose major depression. 
The symptoms cause clinically significant distress or impairment in social ,occupational, or 
other important areas of functioning.        
          The stroke patients  are evaluated for depression for 2 weeks using the above 
Diagnostic  and  statistical  manual  IV   criteria.The  hemisphere  side  associated  with 
depression  is  noted.The  post  stroke  depression  association  with  patient’s  age,  sex, 
hypertension, diabetes ,smoking, alcohol,disability is also studied
  
    STATISTICAL METHOD:
                                 All the data obtained were statistically analysed by using Pearson’s Chi  
square test  and the values were considered significant if the p value is <0.05      .
                                                    RESULTS
            
 POST STROKE  DEPRESSION :  INCIDENCE
       60 stroke patients were selected for evaluation of depression. Unconcious patients, aphasic 
patients, patients with respiratory, kidney, and liver failure  were excluded from study. Patients with 
severe disabling musculo skeletal disorder, cancer, neurodegenerative disorders, pre-existing 
dementia ,recurrent unipolar or bipolar disorder prior to the stroke were also excluded. Stroke patients 
presenting within 30 days were selected for study.
           Total cases taken for study:                    60 
           Patients with post stroke depression:     16 [26.7%]
           Patients without post stroke depression:  44 [73.3%]
          
             Out of the 60 cases selected, 16 patients had post stroke depression.26.7% of stroke patients 
had post stroke depression
.
POST STROKE DEPRESSION: ASSOCIATIONS
AGE AND POST STROKE  DEPRESSION:[PSD]
NO PSD PSD PRESENT Total
Age less than 40 
years
2[66.7%] 1[33.3%] 3
Age 40 to 60 years 31[70.5%] 13[29.5%] 44
Age more than 60 
years
11[84.6%] 2[15.4%] 13
Total 44[73.3%] 16[26.7%] 60
NO PSD PSD PRESENT TOTAL
Age less than or equal to 
60 years
33[70.2%] 14[29.8%] 47
Age more than 60 years 11[84.6%] 2[15.4%] 13
Total 44[73.3%] 16[26.7%] 60
   
  The younger age patients were commonly associated with depression. Around 30% of  stroke patients 
with age less than or equal to 60 years were associated with post stroke depression while around 15% 
of patients with age more than 60 years were associated with depression.It is statistically insignificant.
[P=0.57]
SEX AND POST STROKE  DEPRESSION:[PSD]
   P=0.49
HYPERTENSION AND POST STROKE DEPRESSION:
NO PSD  PSD PRESENT
NON-HT 22[75.9%] 7[24.1%]
HT 22[71.0%] 9[29%]
TOTAL 44 16
:
P=0.67
DIABETES AND POST STROKE DEPRESSION:
P=0.42
 
NO PSD  PSD PRESENT
Male 29 [76.3%] 9[23.7%]
Female 15[68.2%] 7[31.8%]
TOTAL 44 16
 NO PSD  PSD PRESENT
NON DM 37[75.5%] 12[24.5%]
DM 7[63.6%] 4[36.4%]
TOTAL 44 16
ISCHEMIC HEART DISEASE AND POST STROKE DEPRESSION:
P=0.16
SMOKING AND POST STROKE DEPRESSION:
   
NO PSD PSD PRESENT
NON SMOKER 25[69.4%] 11[30.6%]
SMOKER 19[79.2%] 5[20.8%]
TOTAL 44 16
P=0.4
ALCOHOL AND POST STROKE DEPRESSION:
NO PSD PSD PRESENT
NONALCOHOLIC 27[69.2%] 12[30.8%]
ALCOHOLIC 17[81%] 4[19%]
TOTAL 44 16
P=0.33
NO PSD PSD PRESENT
NO IHD 39[70.9%] 16[29.1%]
IHD 5[100%] 0
TOTAL 44 16
  
HEMISPHERE SIDE AND POST STROKE  DEPRESSION:
NO PSD PSD PRESENT Total
Right hemisphere 29[82.9%] 6[17.1%] 35
Left hemisphere 15[60%] 10[40%] 25
Total 44[73.3%] 16[26.7%] 60
            P=0.05.
       The  left  hemisphere stroke  showed  increased  incidence  of  depression  compared  to  right 
hemisphere stroke,which is statistically significant[p=0.05]. The left hemisphere stroke showed around 
40% of depression while right hemisphere stroke showed 17% post stroke depression. 
DISABILITY AND  POST STROKE DEPRESSION:
NO PSD PSD PRESENT
HEMIPARESIS 31[73.8%] 11[26.2%]
HEMIPLEGIA 13[72.2%] 5[27.8%]
TOTAL 44 16
TYPE OF CVA AND POST STROKE  DEPRESSION:
NO PSD PSD PRESENT
INFARCT 40[71.4%] 16[28.6%]
HEMORRHAGE 4[100%] 0
TOTAL 44 16
              P=0.21
                                Association of  post stroke depression with age, sex, hypertension, 
diabetes,  ischemic  heart  disease,  alcohol,  smoking,  hemisphere  side,  disability  were 
studied.  Female  and  male  patients  had  31.8%  and  23.7%  of  post  stroke  depression 
respectively   which  is  statistically  insignificant.  Hypertension  ,Ischemic  heart  disease, 
diabetes  ,smoking,  alcohol   association  with  post  stroke  depression   is  statistically 
insignificant.  Left  hemisphere  stroke patients  showed statistically  significant depression.
[P=.05]   
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.                                 DISCUSSION  
INCIDENCE:
              In this study ,60 stroke  patients were taken for evaluation of depression.38 cases 
of male stroke patients and 22 cases of female stroke patients were studied.26.7% of stroke 
patients were associated with depression.
           R Pohjasvaara T, Leppavuori A ,Siira I, Vataja  , Kaste M, Erkinjuntti T    
in their study found  that the prevalence of  post stroke depression varies enormously [from 
5  %  to  50%]  depending  on  several  factors,  including   the  criteria  used  to  diagnose 
depression,  area  of  involvement  ,  and  how  long  after  the  stroke  the  assessment  is 
made[7,26].
SEX
           Female stroke patients had a increased chance of depression compared to male 
patients  which  is  comparable  to  incidence  of  depression  in  general  population.31.8%of 
female patients has depression compared to 23.7% of male patients..
           [ Anderson et al 1995,Herrmann et al 1998, Kotila et al 1998, paradiso and Robinson 
1998]
AGE:
            The younger age is commonly associated with post stroke depression. Around 
30%of patients with  age less than or equal to 60 years were commonly associated with 
depression while around 15% of patients with age more than 60 years were associated with 
depression.[6]
           [Neau et al 1998,Paradiso and Robinson 1998]
HEMISPHERE SIDE:
       The  hemisphere  side  played  a  major  role  in  determining  the  depression.  Left 
hemisphere stroke showed increased incidence of depression compared to right hemisphere 
stroke, which is statistically significant[p=0.05].The left 
      hemisphere stroke showed 40% post stroke depression while right hemisphere 
      stroke showed 17% post stroke depression.[22,24]
                            Rockville M.D in his study made out the frontal and left hemisphere  
stroke are strongly associated with depression[8]. A large MRI study  from  Finland has 
reported  a  significant  increase  in  depression   following  left  hemisphere  and  frontal 
stroke[9].MRI has greater accuracy than CT and frontal subcortical  circuits are recognized 
as the neuroanatomical substrate of much of the depression syndrome[10]
DISABILITY:
                   In this study, the disability  is not  related to depression .The patients with 
weakness less than or equal to 3 showed 28% of depression while patients with weakness 
more than 3 showed 26 % of depression. This is statistically insignificant.
                    At  1997,  Alexoplus  and Krishnan coined the  term “VASCULAR 
DEPRESSION” to describe depression associated with stroke. Vascular depression includes 
both Post stroke depression and MRI detected cerebral  infarction in which there are no 
clinical symptoms such as focal neurological deficit. When the infarct obstructs neuronal 
network related to mood, the patient is predisposed to depression. Neurological factors are 
more  prominent  than  genetic  factors  or  psychosocial  stress  in  patients  with  vascular 
depression.[20]
          Folstein et al found a significantly increased rate of depression in stroke patients 
compared to orthopedic patients despite similar levels of disability, suggesting that mood 
dysregulation is a more specific complication of stroke rather than a general response to 
disability.[24]
DIABETES:
        Patients with diabetic has showed increased depression compared to non diabetic. Non 
diabetic with stroke showed 25% incidence of depression while the diabetic with stroke 
showed 36%.This is explained by the depression associated with hyperglycemic levels and 
diabetic complications.[Harrisons]
 
             In this study hypertension, ischemic heart disease, smoking, alcohol did not have 
significant association with depression  in stroke patients.
                LIMITATIONS:
     The localization of infarct to the particular area in a hemisphere is difficult because of 
early CT scanning of the brain which will not pick up the infarct area.
       This limitation made to limit the study to right or left hemisphere association with 
depression.
       MRI scanning of the brain would help to localize the area of hemisphere concerned 
with depression. The proximity of infarct to the left   frontal lobe determines depression 
according to the literature.
 CONCLUSION
   1.27% of stroke patients developed post stroke depression.
   2.The left hemisphere stroke is commonly associated with depression.
   3.Post stroke depression is common in younger age patients .
   4.The severity of disability is not related to depression.
IN  SUMMARY,  DEPRESSION  IS  COMMON  FOLLOWING  THE  STROKE  AND 
IDENTIFYING  POST  STROKE  DEPRESSION  WILL  HELP  TO  IMPROVE  THE 
PHYSICAL,COGNITIVE  AND  INTELLECTUAL  RECOVERY  OF  STROKE 
PATIENTS USING ANTIDEPRESSANTS.
   
     BIBLIOGRAPHY 
1.Depression  and  stroke:  National  institute  of  mental  health;  National  institute  of 
health….US Department of health and human services.
2.Know stroke, Know the signs, Act in time. National institute of neurological disorder and 
stroke 2001.
3.Depression guideline panel. Clinical practice guideline number5. Depression in primary 
care:  Volume  1  Detection  and  diagnosis.  AHCPR  pub.no.93  to 
0551.RockvilleMD:USdepartment  of  health  and  human  services.Agency  for  health  care 
policy and research1993.
4.Archieves of general Psychiatry 1993:  Regier DA :50[2] ;  85-94
5.American journal of psychiatry 1993,150[10]:  1447-65
6.Stroke and depression- Robert Robinson,University of IOWA Hospitals and clinics
7. R Pohjasvaara T, Leppavuori A ,Siira I, Vataja  , Kaste M, Erkinjuntti T .Frequency and 
clinical determinants of post stroke depression  stroke 1998:29[11]:2311-17
8.Post  stroke  Rehabilitation  guideline  panel:  Post  stroke  Rehabilitation  clinical  practice 
guideline No; 16  US Department of health and human services Rockville,MD ,AHCPR 
Pub.no.95-0662 May 1995
9.Vataja R,Poohjasvaara T , Leppavuori A, Mantyla R, Aronen H J, Salonen O et al: MRI 
correlates of depression after ischemic stroke.Arch Gen Pysch 2001  58[10]925-31
10.Mayberg  H  .Depression  and  frontal  subcortical  circuits.  In:Lichter  DG,Cummings 
JL,editors: Frontal subcortical circuits in psychiatric and neurologic disorders.London: The 
Guilford press:2001:177-206
11.Thomas  AJ,  Kalaria  RN,  O  Brien  JT.  Depression  and  vascular  diseases:J  Aff  Dis 
2004:79:81-95
12.House A ,Dennis M, Molyneux A, Warlow C,Hawton K. Emotionalism after stroke BMJ 
1989  298 [6679]:991-4
13.Herrmann et  al  1998—CNS forum Herrmann N,Black SE,  Lawerence J  ,Szekely C, 
Szalei.The sunny stroke study:stroke 1998 29[3] 618-24
14.Morris  PL,  Robinson  RG  ,Andrzejewski  P,  Samuels  J,  Price  TR  ,  :Association  of 
depression with10 year post stroke mortality  Am.J Psych 1993 150[1]:124-9
15.Jorge  RE  ,Robinson  RG  ,  Arndts,  Starkstein  S.   Mortality  and  post  stroke 
depression:Amj psych 2003 160[10]:1823-9
16.Robinson  RG,  Schultz  SK,  Cartillo  C,  KopelT,   Kosier  JT,  Newman  RM  et  al 
Nortryptline vs Fluoxetine in PSD      Amj.Pysch 2000  157[3]:351-9
17.Glassmann AH, O’Connor CM, Califf PM, Swedberg K, Schwartz P,Bigger JT  JAMA 
2002    288[6]   701-9
18.Starkstein SE, Robinson RG, Depression in cereberovascular disease   Baltimore:John 
Hopkins  University Press, 1993:28-49
19.Astrom M  Adolfsson R,  Asplund K Major  depression in  stroke patients:   a  3 year 
longitudinal study. Stroke1993:24:976-982
20.Fujikawa T, National Hospital Organization, Kamo psychiatry medical centre  Seishin 
Shinkeigaku- pyschiatria et neurologic Japonica 106[4] 421-30,2004
21.Depression after stroke -   a  prospective epidemiological study—Whyte E    .Mulsant 
BH,   Vanderbilt J,    Dodge  HH, Ganguli M,   Journal of the American Geriatrics society 
52[5]  774-8, 2004 May
22.A Reappraisal of PSD,intra and inter hemispheric lesion location using meta analysis: 
Narushima K, Kosier JT, Robinson RG, :Journal of neuro psychiatry and clinical neuro 
sciences  422-30,2003
23.Starkstein SE, Robinson RG, :Neuropyschiatric aspects of cerebero vascular disorders in 
The American Pyschiatry textbook of Neuropyschiatry  1992:449-472
24.Robinson RG, Starkstein SE, Current research in affective disorders following stroke..J 
Neuropysch.clin. Neurosciences  1990 2[l]:1-14
25.Parikh RM,Robinson RG,Lipsey  JR  et al.  The impact on post stroke depression on 
recovery  in  activities  of  daily  living over  a  2  year  follow up.  .Arch  Neurol   1990:47 
785-789
26.House A ,Dennis M,Warlow c et al Mood disorders after stroke and their relation to 
lesion location  Brain 1990: 113: 1113-1129
27.Marin RS, Fogel BS, Hawkins J et al Apathy, a treatable syndrome J. Neuro Psychiatry 
Clin. Neurosciences 1995 7 (l): 23-30
28.ADAMS  HP  et  al:Guidelines  for  the  early  management  of  patients  with  stroke:A 
scientific  statement  from  the  stroke  council  of  the  American  stroke 
association.Stroke:1056,2003.
29. KESSLER RL et al:The epidemology of major depressive disorder. Results from the 
National comorbidity survey Replication [NCSR] JAMA289:3095,2003
30.Harrison’s principles of internal medicine 16 th edition
. 
       31.   ALBERS GW et al: Antithrombotic and thrombolytic therapy for ischemic stroke. 
Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 114:683S, 1998.
     32. GORTER JW: Major bleeding during anticoagulation after cerebral ischemia: Patterns 
and risk factors.  Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial 
Fibrillation Trial (EAFT) study groups. Neurology 53:1319, 1999
33.INZITARI D et al: The causes and risk of stroke in patients with asymptomatic internal-
carotid-artery stenosis. N Engl J Med 342:169, 2000
34.LAUPACIS A et al: Antithrombotic therapy for atrial fibrillation. Chest 114:579S, 1998
35.CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with 
acute  ischaemic  stroke.  CAST  (Chinese  Acute  Stroke  Trial)  Collaborative  Group.  Lancet 
349:1641, 1997
36.ADAMS HJ et al: Guidelines for the Management of Patients with Acute Ischemic Stroke. 
A statement for healthcare professionals from a Special Writing Group of the Stroke Council, 
American Heart Association. Stroke 25:1901, 1994
37.AMARENCO P et al: Atherosclerotic disease of the aortic arch and the risk of ischemic 
stroke. N Engl J Med 331:1474, 1994
38.ATRIAL  FIBRILLATION  INVESTIGATORS:  Risk  factors  for  stroke  and  efficacy  of 
antithrombotic  therapy in  atrial  fibrillation.  Analysis  of  pooled  data  from five  randomized 
controlled trials. Arch Intern Med 154:1449, 1994
39.EAFT  (EUROPEAN  ATRIAL  FIBRILLATION  TRIAL)  STUDY  GROUP:  European 
Atrial Fibrillation Trial: Secondary prevention of vascular events in patients with nonrheumatic 
atrial  fibrillation  and  recent  transient  ischemic  attack  or  minor  ischemic  stroke.  Lancet 
342:1255, 1993
40.FISHER M et al: Prophylactic neuroprotection for cerebral ischemia. Stroke 25:1075, 1994
41.STROKE  PREVENTION  IN  ATRIAL  FIBRILLATION  INVESTIGATORS:  Warfarin 
versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in 
Atrial Fibrillation II Study. Lancet 343:687, 1994
42.THE SALT COLLABORATORS GROUP: Swedish Aspirin Low-dose Trial (SALT) of 75-
mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345, 
1991
43.WILTERDINK JL,  EASTON JD:  Vascular  event  rates  in  patients  with  atherosclerotic 
cerebrovascular disease. Arch Neurol 49:857, 1992
PROFORMA
Name                      Age                       Sex             IP number
 Complaints
  H/O Present illness:
  Past History:   Hypertension
                      :  Diabetes mellitus
                        :Ischemic Heart disease
                       :  Heart,Respiratory,Kidney or Liver failure
                       :Neurodegenative disorders like Parkinsons disease,Alzeimer’s
                                      disease,Multiple system atrophy,Huntington’s disease. 
Personal history: Smoking ,
                             Alcohol
General Examination:    
Vital signs:   Pulse rate
                     Blood pressure
Systemic examination:
     Central Nervous system:
                       Higher function: Level of conciousness
                                                  Orientation
                                                  Intelligence
                                                  Memory
                                                  Sleep
                                                  Speech and language:Dysarthria
                                                                Aphasia:Motor,sensory and global aphasia
                         Cranial nerves:
                        Motor system:   Bulk
                                               Tone
                                                Power
                                                Reflexes
                                                Co-ordination of movements
                                               Gait and involuntary movements
                         Sensory system: Light touch,position sense,Recognition of size,shape,weight 
and form,vibration,pain,temperature.
   Clinical diagnosis:
    CT Diagnosis and other baseline investigations,ECG,CXR
    Diagnosis if depression using DSM  IV criteria[Diiagnostic and statistical manual]

